158 related articles for article (PubMed ID: 29695292)
1. A biomarker study in long-lasting amnestic mild cognitive impairment.
Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic and prognostic value of tau-PET in amnestic MCI with different FDG-PET subtypes.
Boccalini C; Caminiti SP; Chiti A; Frisoni GB; Garibotto V; Perani D;
Ann Clin Transl Neurol; 2024 May; 11(5):1236-1249. PubMed ID: 38553802
[TBL] [Abstract][Full Text] [Related]
3. Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data.
Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
Alzheimers Dement; 2014 Nov; 10(6):704-12. PubMed ID: 24613706
[TBL] [Abstract][Full Text] [Related]
4. FDG-PET markers of heterogeneity and different risk of progression in amnestic MCI.
Caminiti SP; De Francesco S; Tondo G; Galli A; Redolfi A; Perani D; ;
Alzheimers Dement; 2024 Jan; 20(1):159-172. PubMed ID: 37505996
[TBL] [Abstract][Full Text] [Related]
5. The Memory Alteration Test Is Correlated with Clinical, Cerebrospinal Fluid, and Brain Imaging Markers of Alzheimer Disease in Lima, Peru.
Custodio N; Malaga M; Montesinos R; Chambergo-Michilot D; Baca F; Carbajal JC; Huilca JC; Herrera-Perez E; Lira D; Diaz MM; Lanata S
Dement Geriatr Cogn Disord; 2023; 52(5-6):309-317. PubMed ID: 37827146
[TBL] [Abstract][Full Text] [Related]
6. Vigorous, regular physical exercise may slow disease progression in Alzheimer's disease.
Devanand DP; Masurkar AV; Wisniewski T
Alzheimers Dement; 2023 Apr; 19(4):1592-1597. PubMed ID: 36722738
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series.
Prestia A; Caroli A; Herholz K; Reiman E; Chen K; Jagust WJ; Frisoni GB; ;
Alzheimers Dement; 2013 Nov; 9(6):677-86. PubMed ID: 23375562
[TBL] [Abstract][Full Text] [Related]
8. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
Schneider LS; Kennedy RE; Cutter GR;
Alzheimers Dement; 2010 Sep; 6(5):367-77. PubMed ID: 20813339
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
[TBL] [Abstract][Full Text] [Related]
10. Predicting MCI outcome with clinically available MRI and CSF biomarkers.
Heister D; Brewer JB; Magda S; Blennow K; McEvoy LK;
Neurology; 2011 Oct; 77(17):1619-28. PubMed ID: 21998317
[TBL] [Abstract][Full Text] [Related]
11. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment.
Barrio JR; Kepe V; Satyamurthy N; Huang SC; Small G
J Nutr Health Aging; 2008 Jan; 12(1):61S-5S. PubMed ID: 18165848
[TBL] [Abstract][Full Text] [Related]
12. Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy.
Lesman-Segev OH; La Joie R; Stephens ML; Sonni I; Tsai R; Bourakova V; Visani AV; Edwards L; O'Neil JP; Baker SL; Gardner RC; Janabi M; Chaudhary K; Perry DC; Kramer JH; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2019; 24():102025. PubMed ID: 31670152
[TBL] [Abstract][Full Text] [Related]
13. Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis.
Stage EC; Svaldi D; Phillips M; Canela VH; Duran T; Goukasian N; Risacher SL; Saykin AJ; Apostolova LG;
Alzheimers Res Ther; 2020 Aug; 12(1):93. PubMed ID: 32758274
[TBL] [Abstract][Full Text] [Related]
14. Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?
Teipel S; Grothe MJ;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):526-36. PubMed ID: 26555082
[TBL] [Abstract][Full Text] [Related]
15. Hybrid PET/MRI with Flutemetamol and FDG in Alzheimer's Disease Clinical Continuum.
Atay LO; Saka E; Akdemir UO; Yetim E; Balcı E; Arsava EM; Topcuoglu MA
Curr Alzheimer Res; 2023; 20(7):481-495. PubMed ID: 38050727
[TBL] [Abstract][Full Text] [Related]
16. CSF markers of AD-related pathology relate specifically to memory impairment in older people with HIV: a pilot study.
Lobo JD; Moore DJ; Bondi MW; Soontornniyomkij V; Soontornniyomkij B; Gouaux B; Achim CL; Ellis RJ; Sundermann EE
J Neurovirol; 2022 Feb; 28(1):162-167. PubMed ID: 35103880
[TBL] [Abstract][Full Text] [Related]
17. Abnormal motor cortical plasticity as a useful neurophysiological biomarker for Alzheimer's disease pathology.
Murakami T; Abe M; Tiksnadi A; Nemoto A; Futamura M; Yamakuni R; Kubo H; Kobayashi N; Ito H; Hanajima R; Hashimoto Y; Ugawa Y
Clin Neurophysiol; 2024 Feb; 158():170-179. PubMed ID: 38219406
[TBL] [Abstract][Full Text] [Related]
18. Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration.
Levin F; Ferreira D; Lange C; Dyrba M; Westman E; Buchert R; Teipel SJ; Grothe MJ;
Alzheimers Res Ther; 2021 Feb; 13(1):49. PubMed ID: 33608059
[TBL] [Abstract][Full Text] [Related]
19. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment.
Chandra A; Valkimadi PE; Pagano G; Cousins O; Dervenoulas G; Politis M;
Hum Brain Mapp; 2019 Dec; 40(18):5424-5442. PubMed ID: 31520513
[TBL] [Abstract][Full Text] [Related]
20. The value of FDG combined with PiB PET in the diagnosis of patients with cognitive impairment in a memory clinic.
Liu F; Shi Y; Wu Q; Chen H; Wang Y; Cai L; Zhang N
CNS Neurosci Ther; 2024 Feb; 30(2):e14418. PubMed ID: 37602885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
